Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage

Published 01/08/2025, 13:06
© Reuters

Investing.com -- Eli Lilly (NYSE:LLY) stock rose 1.3% and Novo Nordisk (NYSE:NVO) shares jumped 2% Friday morning after The Washington Post reported that Medicare and Medicaid programs are planning to experiment with covering weight loss drugs.

According to documents obtained by the newspaper, the Trump administration is developing a five-year experiment that would allow state Medicaid programs and Medicare Part D insurance plans to voluntarily cover GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound for weight management purposes.

This marks a significant shift in policy, as Medicare currently covers these medications primarily for patients with Type 2 diabetes, not obesity. The experiment signals the administration may be open to broader coverage of these drugs through government insurance programs.

The proposed experiment is expected to begin in April 2026 for Medicaid and January 2027 for Medicare plans. It will be conducted through the Center for Medicare and Medicaid Innovation (CMMI), which tests new healthcare payment approaches aimed at reducing costs while improving care quality.

This initiative provides an alternative pathway for Medicare and Medicaid patients to access anti-obesity medications after the administration stated in April that neither program would cover GLP-1s for weight loss. The new plan effectively replaces a previous Biden administration proposal from last year that would have enabled the programs to cover these drugs for patients with obesity.

GLP-1 drugs have gained significant attention for their effectiveness in weight management, with many private insurance plans already covering them for obesity treatment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.